Stock Traders Purchase Large Volume of Ginkgo Bioworks Call Options (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was the recipient of some unusual options trading on Monday. Investors acquired 19,822 call options on the stock. This represents an increase of approximately 387% compared to the average daily volume of 4,068 call options.

Insider Activity at Ginkgo Bioworks

In related news, insider Mark E. Dmytruk sold 39,569 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total transaction of $47,878.49. Following the completion of the sale, the insider now owns 761,737 shares in the company, valued at approximately $921,701.77. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Mark E. Dmytruk sold 51,169 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the completion of the transaction, the insider now directly owns 865,079 shares of the company’s stock, valued at approximately $908,332.95. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark E. Dmytruk sold 39,569 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the completion of the transaction, the insider now directly owns 761,737 shares of the company’s stock, valued at $921,701.77. The disclosure for this sale can be found here. 15.05% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of large investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its position in Ginkgo Bioworks by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 130,334 shares of the company’s stock valued at $236,000 after buying an additional 7,499 shares during the last quarter. Raymond James & Associates boosted its position in Ginkgo Bioworks by 4.6% in the 3rd quarter. Raymond James & Associates now owns 193,589 shares of the company’s stock valued at $350,000 after buying an additional 8,455 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Ginkgo Bioworks by 12.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 79,843 shares of the company’s stock valued at $145,000 after buying an additional 8,615 shares during the last quarter. Cerity Partners LLC boosted its position in Ginkgo Bioworks by 5.3% in the 4th quarter. Cerity Partners LLC now owns 209,613 shares of the company’s stock valued at $354,000 after buying an additional 10,472 shares during the last quarter. Finally, QCM Cayman Ltd. boosted its position in Ginkgo Bioworks by 56.5% in the 3rd quarter. QCM Cayman Ltd. now owns 32,446 shares of the company’s stock valued at $59,000 after buying an additional 11,716 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Trading Up 12.9 %

NYSE DNA traded up $0.11 during trading hours on Monday, reaching $0.97. 56,801,735 shares of the company’s stock were exchanged, compared to its average volume of 26,079,813. The stock has a market cap of $2.09 billion, a PE ratio of -2.04 and a beta of 1.36. Ginkgo Bioworks has a one year low of $0.74 and a one year high of $2.55. The firm has a fifty day moving average of $1.13 and a 200-day moving average of $1.34.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $34.76 million for the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative return on equity of 48.23% and a negative net margin of 355.08%. The firm’s revenue was down 64.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.04) earnings per share. As a group, research analysts forecast that Ginkgo Bioworks will post -0.32 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DNA. TD Cowen dropped their target price on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a report on Friday, March 1st. The Goldman Sachs Group dropped their target price on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a report on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus price target of $2.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.